Contribution of pharmaceutical innovation to longevity growth in Germany and France, 20017

21Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.
Get full text

Abstract

This paper investigates the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. The effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany is examined, using longitudinal, annual, state-level data during the period 20017. The estimates imply that about one-third of the 1.4-year increase in German life expectancy during the period 20017 was due to the replacement of older drugs by newer drugs. The effect of the vintage of chemotherapy treatments on age-adjusted cancer mortality rates of residents of France is also investigated, using longitudinal, annual, cancer-site-level data during the period 20026. The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer mortality rates, and may have accounted for as much as half of the decline. © 2012 Adis Data Information BV. All rights reserved.

Cite

CITATION STYLE

APA

Lichtenberg, F. R. (2012). Contribution of pharmaceutical innovation to longevity growth in Germany and France, 20017. PharmacoEconomics. Springer International Publishing. https://doi.org/10.2165/11587150-000000000-00000

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free